ID
25654
Description
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Non-serious adverse events
Keywords
Versions (4)
- 8/12/17 8/12/17 -
- 8/12/17 8/12/17 -
- 8/18/17 8/18/17 -
- 9/8/17 9/8/17 -
Uploaded on
September 8, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Non-serious adverse events GSK study Dyskinesia in Parkinson's disease NCT00363727
Non-serious adverse events GSK study Dyskinesia in Parkinson's disease NCT00363727
Description
Non-serious adverse events
Description
If Yes, record details below. Note: If this is a Serious Adverse Event (SAE), do not complete this form, go to the SAE section and complete the SAE form.
Data type
boolean
Alias
- UMLS CUI [1]
- C1518404
Description
Diagnosis Only (if known). Otherwise Sign/Symptom
Data type
text
Alias
- UMLS CUI [1]
- C0441471
Description
Start date
Data type
date
Alias
- UMLS CUI [1]
- C0808070
Description
Outcome
Data type
integer
Alias
- UMLS CUI [1]
- C1705586
Description
End Date
Data type
date
Alias
- UMLS CUI [1]
- C0806020
Description
Maximum Intensity
Data type
text
Alias
- UMLS CUI [1,1]
- C0518690
- UMLS CUI [1,2]
- C0877248
Description
Action Taken
Data type
text
Alias
- UMLS CUI [1]
- C2826626
Description
withdrawal
Data type
boolean
Alias
- UMLS CUI [1,1]
- C2349954
- UMLS CUI [1,2]
- C1519255
Description
AE caused by the investigational product
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0085978
- UMLS CUI [1,2]
- C0877248
Similar models
Non-serious adverse events GSK study Dyskinesia in Parkinson's disease NCT00363727
C0678257 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
C0443172 (UMLS CUI-2)
(Comment:en)
C0178602 (UMLS CUI-2)
(Comment:en)
(Comment:en)
C1519255 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,2])
No comments